Shanghai Ark Biopharmaceutical

CompanyChina

Shanghai Ark Biopharmaceutical develops one asset, in phase 2 (AK0406 in influenza prevention). Mostly other; based in China.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1
  • AK0406

    Long-acting antiviral drug-Fc conjugate intended to prevent influenza.

    Phase 2, Other, influenza prevention

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1
  • Similar companies1

Intelligence